Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Michael Burgess, MD, PhD

    TitleAssistant Clinical Professor
    SchoolUCSF School of Medicine
    Address995 Potrero Ave WARD 86
    San Francisco CA 94110
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, San FranciscoFellowshipHematology and Medical Oncology2012
      University of California, San FranciscoResidency Internal Medicine2009
      David Geffen School of Medicine at UCLAM.D.Medicine2007
      University of California, Los AngelesPh.D.Molecular Biology2005
      University of California, BerkeleyB.A.Molecular and Cell Biology1997

      Collapse Overview 
      Collapse Interests
      Acute Myeloid Leukemia, Myelodysplastic Syndromes, Early Clinical Development, Biomarker Discovery

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K. Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. Elife. 2015; 4. PMID: 26193121; PMCID: PMC4569895.
      2. Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014 Dec 18; 124(26):3947-55. PMID: 25361812; PMCID: PMC4271180.
      3. Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers CL. MAGI-2 scaffold protein is critical for kidney barrier function. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14876-81. PMID: 25271328; PMCID: PMC4205655.
      4. Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal. 2013 Dec 3; 6(304):ra105. PMID: 24300897; PMCID: PMC4117477.
      5. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19466-71. PMID: 17164333; PMCID: PMC1698443.
      6. Burgess MR, Sawyers CL. Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal. 2006; 6:918-30. PMID: 16906325.
        View in: PubMed
      7. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005 Mar 1; 102(9):3395-400. PMID: 15705718; PMCID: PMC552942.
      Michael's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP